Clinical trial
A Phase 2a Clinical Trial to Assess the Safety and Efficacy of C3 Inhibitor AMY-101, in Adults With Gingivitis
NCT03694444 is registered in ClinicalTrials.gov with Amyndas Pharmaceuticals S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Clinical Trial to Assess the Safety and Efficacy of C3 Inhibitor AMY-101, in Adults With Gingivitis
- Lead sponsor
- Amyndas Pharmaceuticals S.A.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 22, 2019
- Completion date
- October 30, 2020
- Enrollment
- 39 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.